World Library  
Flag as Inappropriate
Email this Article


Article Id: WHEBN0003986292
Reproduction Date:

Title: Sb-649,868  
Author: World Heritage Encyclopedia
Language: English
Subject: Suvorexant, SB-408,124, TCS-OX2-29, SB-334,867, SNAP-94847
Collection: Hypnotics, Orexin Antagonists, Sedatives
Publisher: World Heritage Encyclopedia


Systematic (IUPAC) name
Clinical data
Legal status
  • Investigational
ATC code None
PubChem CID:
Chemical data
Formula C26H24FN3O3S
Molecular mass 477.549 g/mol (free base)

SB-649,868 is a dual orexin receptor antagonist in development by GlaxoSmithKline.[1] The drug is currently in phase II development for insomnia.

A phase I study evaluated doses up to 80 mg, resulting in significant improvement in sleep latency without adverse effects.[2]

In randomized, double-blind, placebo-controlled crossover trials, the 10 and 30 mg doses increased sleep time and reduced sleep latency.[3] The subsequent study added a 60 mg dose and observed dose-dependent sleep promotion.[4]

See also


  1. ^ Renzulli C, Nash M, Wright M, Thomas S, Zamuner S, Pellegatti M, Bettica P, Boyle G (February 2011). "Disposition and metabolism of [14C]SB-649868, an orexin 1 and 2 receptor antagonist, in humans" (PDF). Drug Metab. Dispos. 39 (2): 215–27.  
  2. ^ "Phase I studies on the safety, tolerability, pharmacokinetics and pharmacodynamics of SB-649868, a novel dual orexin receptor antagonist.". Journal of Psychopharmacology 26: 1058–1070. Aug 2012.  
  3. ^ "Differential effects of a dual orexin receptor antagonist (SB-649868) and zolpidem on sleep initiation and consolidation, SWS, REM sleep, and EEG power spectra in a model of situational insomnia.". Neuropsychopharmacology 37: 1224–33. Apr 2012.  
  4. ^ "The orexin antagonist SB-649868 promotes and maintains sleep in men with primary insomnia.". Sleep 35: 1097–104. Aug 2012.  

Further reading

  • Ratti E (December 13, 2007). "Psychiatry: An Innovative Drug Discovery Pipeline" (PDF) (GSK Neurosciences seminar). Archived from the original on December 5, 2008. 
  • Scammell TE, Winrow CJ (February 2011). "Orexin receptors: pharmacology and therapeutic opportunities". Annu. Rev. Pharmacol. Toxicol. 51: 243–66.  
This article was sourced from Creative Commons Attribution-ShareAlike License; additional terms may apply. World Heritage Encyclopedia content is assembled from numerous content providers, Open Access Publishing, and in compliance with The Fair Access to Science and Technology Research Act (FASTR), Wikimedia Foundation, Inc., Public Library of Science, The Encyclopedia of Life, Open Book Publishers (OBP), PubMed, U.S. National Library of Medicine, National Center for Biotechnology Information, U.S. National Library of Medicine, National Institutes of Health (NIH), U.S. Department of Health & Human Services, and, which sources content from all federal, state, local, tribal, and territorial government publication portals (.gov, .mil, .edu). Funding for and content contributors is made possible from the U.S. Congress, E-Government Act of 2002.
Crowd sourced content that is contributed to World Heritage Encyclopedia is peer reviewed and edited by our editorial staff to ensure quality scholarly research articles.
By using this site, you agree to the Terms of Use and Privacy Policy. World Heritage Encyclopedia™ is a registered trademark of the World Public Library Association, a non-profit organization.

Copyright © World Library Foundation. All rights reserved. eBooks from World eBook Library are sponsored by the World Library Foundation,
a 501c(4) Member's Support Non-Profit Organization, and is NOT affiliated with any governmental agency or department.